StreetAlpha.app
Home › Stocks › ACAD

Acadia Pharmaceuticals Inc (ACAD)

Healthcare
$18.32
▼ −1.87%
LAST CLOSE · NOV 17

Acadia Pharmaceuticals develops and sells medicines for neurological and rare diseases, including NUPLAZID and DAYBUE. It last closed at $18.32 on Nov 17, down 1.87% on the day. The average 12-month price target from 10 analysts is $32.20 (+75.8% from the last close), with a high of $38.00 and a low of $23.00. Analyst consensus is Strong Buy, based on the latest ratings from 10 firms (8 buy, 2 hold, 0 sell). In the past 30 days there were 2 dark pool prints totaling $1.9M, the largest $1.3M.

AI Auto Pilots
Is ACAD in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$1.2B
+14.8% vs a year ago
Net income
$362.2M
+38.7% vs a year ago
EPS (diluted)
$2.12
+36.8% vs a year ago
Free cash flow
$82.0M
6.8% margin
Valuation
Market cap
$3.2B
172.8M shares
P/E
8.6
Price over 12 month EPS
Price to sales
2.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$322.4M
At Sep 30
Shareholder equity
$1.4B
Shares outstanding
172.8M
At Oct 28
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $484.1M$484.1MFY2021FY2022: $517.2M$517.2MFY2022FY2023: $726.4M$726.4MFY2023FY2024: $957.8M$957.8MFY2024FY2025: $1.1B$1.1BFY2025

From ACAD's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 10 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
10firms
8 Buy2 Hold0 Sell
Each firm's latest rating on ACAD in the past 90 days
Average 12-month target
$32.20
▲ 75.8% upside

Based on 10 analysts who set a price target on ACAD in the past 90 days. The average target is $32.20, with a high of $38.00 and a low of $23.00, compared with the last close of $18.32.

Low $23.00Avg $32.20High $38.00
Blue marker: last close $18.32
Highest target$38.00
Average target$32.20
Lowest target$23.00
Latest rating changes
Morgan StanleyTarget lowered
Nov 13Hold$28 → $24
Canaccord GenuityTarget raised
Nov 6Buy$36 → $38
RBC CapitalTarget raised
Nov 5Buy$37 → $38
NeedhamReiterated
Oct 19Buy$35
UBSDowngrade
Oct 13Hold$49 → $23
DateFirmActionRatingPrice target
Nov 13Morgan StanleyTarget loweredHold$28 → $24
Nov 6Canaccord GenuityTarget raisedBuy$36 → $38
Nov 5RBC CapitalTarget raisedBuy$37 → $38
Oct 19NeedhamReiteratedBuy$35
Oct 13UBSDowngradeHold$49 → $23
Loading…

Technical Analysis

ACAD · as of the Nov 17 close · updated after every close
Downtrend

The stock is 7% below its 20 day and 17% below its 50 day average. It is 27% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 40). The nearest support is the Pivot at $18.31, and the nearest resistance the Pivot R1 at $18.68.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 5.5%/day
Key levels
$30.9652 week high+69.0%
$24.37100 day average+33.0%
$23.26200 day average+27.0%
$21.4150 day average+16.9%
$20.57Swing high (Oct 21)+12.3%
$19.6920 day average+7.5%
$18.68Pivot R1+2.0%
$18.32Last close
$18.31Pivot−0.1%
$17.95Pivot S1−2.0%
$15.8852 week low−13.3%
$15.88Swing low (Nov 9)−13.3%
Indicators
RSI (14)39.92Weak, oversold below 30Neutral
MACD-0.80Below its signal lineBearish
Stochastic40.0Middle of its rangeNeutral
ADX (14)32.4Trending down
Williams %R-63.9Oversold below −80, overbought above −20Neutral
CCI (20)-92.3Oversold below −100, overbought above 100Neutral
Rate of change−10.9%Change over 10 sessionsBearish
ATR (14)$1.02Typical daily range, 5.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ACAD

What happened before

See how ACAD did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ACAD usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ACAD has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ACAD in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
2
Notional
$1.9M
Largest print
$1.3M
Loading…

ACAD Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲201 buying vs 152 selling
  • ▼Held by funds -1.3 pts
  • ●Funds holding -2
  • ▼Superinvestors: 1 added, 4 cut
  • ▲Put/call 2.44 to 0.54
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding350352−0.6%
In funds' top 1045−20.0%
Held by funds96.4%97.7%−1.3 pts
New / increased59 / 14246 / 134+11.7%
Reduced / sold out90 / 62110 / 36+4.1%
Put/call ratio0.542.44−77.9%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ACAD institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ACAD is in one of them and how their past ACAD trades turned out.

ACAD in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ACAD in an article yet. Here's the latest on the wider market.

ACAD Congress Trades

All congress trades →
Trades, 12 months
1
Buys
0
0%
Sells
1
100%
People
1
Last filed Sep 22
Who traded ACAD · since 2019
Latest 3 filings
$15K – $50KTraded Jul 29, 2026Filed Sep 22, 2026
Christopher JacobsSell (partial)
$1K – $15KTraded Sep 8, 2020Filed Nov 6, 2020
$1K – $15KTraded Feb 19, 2019Filed Mar 8, 2019
PersonTypeAmountTradedFiledDelay
Donald J TrumpExecutive branchSell$15K – $50KJul 29, 2026Sep 22, 202655 d
Christopher JacobsR · NYSell (partial)$1K – $15KSep 8, 2020Nov 6, 202059 d
Gilbert CisnerosD · CASell$1K – $15KFeb 19, 2019Mar 8, 201917 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Acadia Pharmaceuticals

Acadia Pharmaceuticals is a drug company based in San Diego, California, that develops and sells medicines for neurological and rare diseases. Its main commercial products are NUPLAZID, used for hallucinations and delusions linked to Parkinson's disease psychosis, and DAYBUE, used to treat Rett syndrome. The company also develops earlier-stage product candidates, including treatments for Alzheimer's disease psychosis. Its medicines are prescribed to patients, mainly in the United States.

Headquarters
San Diego, CA
Founded
1993